Sixth Merck Serono spin-off company to focus on gastrointestinal immunological disorders

05-Mar-2013 - Switzerland

Merck Serono announced the creation of Calypso Biotech, the sixth spin-off company resulting from its Entrepreneur Partnership Program (EPP). Calypso Biotech was formed around Merck Serono’s R&D portfolio in the field of inflammatory bowel diseases, targeting selected niche indications with high unmet medical needs.

The company is founded by Drs. Yolande Chvatchko and Alain Vicari, two seasoned immunologists with experience in team management and drug discovery expertise.

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances